welcomes you to the new, improved website!
In this noteworthy interview, CTSNet Editor-in-Chief Joel Dunning speaks with Jeffrey Velotta, Assistant Clinical Professor of Surgery at the University of California, San Francisco School of Medicine in San Francisco, California, USA, and a thoracic surgeon at Kaiser Permanente Oakland Medical Center, in Oakland, California, USA, about The Society of Thoracic Surgeons 2026 Expert Consensus on the Multimodal Treatment of Pleural Mesothelioma.
They emphasize the importance of thorough patient selection, specifically highlighting the necessity of surgical biopsy and the role of mediastinal staging, such as endobronchial ultrasound (EBUS). The discussion also covers neoadjuvant and adjuvant therapies, the critical need for surgeon expertise in mesothelioma, and the key elements for successful mesothelioma procedures. Furthermore, they address subjects such as diaphragm, phrenic nerve, pericardium, and isolated recurrences.
The conversation also shifts to clinical outcomes, prioritizing survival extension over quality-of-life, and explores the future of mesothelioma treatment. Additionally, throughout the discussion, they also reflect on other research from major trials such as the MARS 2 trial.
Related Resources
Disclaimer
The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.
